Natalizumab for multiple sclerosis.

Saved in:
Bibliographic Details
Title: Natalizumab for multiple sclerosis.
Authors: Liu C; West China Medical School, West China Hospital, Sichuan University, Chengdu, China.; Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China., Cai Z; Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China., Zhao L; Department of Cardiology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., Zhou M; Department of Neurology, West China Hospital, Sichuan University, Chengdu, China., Zhang L; Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Source: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2025 Aug 06; Vol. 8. Cochrane AN: CD015123. Date of Electronic Publication: 2025 Aug 06.
Publication Type: Journal Article; Systematic Review; Meta-Analysis
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1469-493X
DOI:10.1002/14651858.CD015123.pub2